Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ARQ 501 · 7 trials · 7 indications
| Name | Type | Description |
|---|---|---|
| ARQ 501 | DRUG | - |
| ARQ 501 in combination with gemcitabine | DRUG | - |
Inclusion Criteria: 1. Able to provide signed and dated informed consent document prior to study-specific screening procedures. 2. Histologically or cytologically confirmed locally advanced, recurrent or metastatic SCCHN. 3. Measurable disease per RECIST. 4. ≥ 18 years old. 5. Karnofsky performance...
Top 2 of 4 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520/GEH200521 |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |
ARQ 501 is an investigational small molecule oncology drug developed by Merck & Company, Inc. (MRK). It has been studied in clinical trials for advanced solid tumors, carcinoma, head and neck neoplasms, and pancreatic cancer. It is also known as ARQ 501 in combination with gemcitabine. It is not an approved therapy.
ARQ 501 has been studied in clinical trials for advanced solid tumors, cancer, carcinoma, head and neck neoplasms, and pancreatic cancer. Its clinical program includes a Phase 2 study in squamous cell carcinoma of the head and neck and a Phase 2 study in adult patients with leiomyosarcoma. It is investigational and not approved for any indication.
ARQ 501 is developed by Merck & Company, Inc., which trades under the ticker MRK. The company has sponsored the clinical trials evaluating ARQ 501 in advanced solid tumors, head and neck cancer, leiomyosarcoma, and other cancer types.
ARQ 501 is in Phase 1 development. Its clinical program includes Phase 1 studies and Phase 2 studies, all of which are completed. ARQ 501 is investigational and has not been approved by the FDA for any indication.
ARQ 501 has been evaluated in completed clinical trials including NCT00622063, an extension study for previously treated patients; NCT00524524, an exploratory biomarker study in advanced solid tumors; NCT00358930, a study in squamous cell carcinoma of the head and neck; and NCT00310518, a safety and efficacy study in adult patients with leiomyosarcoma.